This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Conclusions: Antipsychotic-Induced Weight Gain and Metabolic Abnormalities

Daniel E. Casey, MD; Dan W. Haupt, MD; John W. Newcomer, MD; David C. Henderson, MD; Michael J. Sernyak, MD; Michael Davidson, MD; Jean-Pierre Lindenmayer, MD; Steven V. Manoukian, MD, FACC; Mary Ann Banerji, MD; Harold E. Lebovitz, MD; and Charles H. Hennekens, MD

Published: May 1, 2004

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Among patients with schizophrenia, substantial evidence exists that metabolic risk factors for as well as risks of cardiovascular disease are far higher than in the general population. Accumulating evidence also suggests that certain atypical antipsychotic treatments are associated with metabolic disturbances that can further increase risks for developing metabolic/cardiovascular illnesses in patients with schizophrenia. Although precise mechanisms of antipsychotic agent-induced metabolic disturbances are not yet fully elucidated, insulin resistance and weight gain as well as their interrelationships appear to play crucial roles.’ ‹

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 65

Quick Links: